Neuphoria Therapeutics (NEUP) Liabilities and Shareholders Equity (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $34.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 13.34% year-over-year to $34.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.3 million (up 28.05% YoY) and the FY2025 annual result came in at $28.6 million, up 3.4% from the prior year.
• Liabilities and Shareholders Equity eased to $34.8 million in Q1 2026 per NEUP's latest filing, from $36.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $46.8 million in Q2 2022 and bottomed at $18.2 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $28.7 million (2025), against an average of $30.2 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity sank 38.56%; it then soared 101.44% in 2025.
• Tracing NEUP's Liabilities and Shareholders Equity over 5 years: stood at $46.8 million in 2022, then plunged by 38.56% to $28.7 million in 2023, then plunged by 36.79% to $18.2 million in 2024, then jumped by 101.44% to $36.6 million in 2025, then declined by 4.89% to $34.8 million in 2026.
• Per Business Quant, the three latest NEUP Liabilities and Shareholders Equity figures stand at $34.8 million (Q1 2026), $36.6 million (Q4 2025), and $27.3 million (Q3 2025).

Peer Comparison